Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and 131I ablation

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 52, Issue 1, 2008, Pages 2-8

  Salvatore, Barbara ^a,b   Paone, G ^b   Klain, M ^b   Storto, G ^c   Nicolai, E ^a   D'Amico, D ^a   Della Morte, A M ^a   Pace, L ^b,c   Salvatore, M ^b,c  

^a IRCCS SDN   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c CNR   (Italy)

Author keywords

Fluorodeoxyglucose F18; Thyroglobulin; Thyroideal neoplasms; Tomography, emission computed

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; LEVOTHYROXINE; THYROGLOBULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG RESPONSE; DRUG UPTAKE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TUMOR DIFFERENTIATION; WHOLE BODY SCINTISCANNING;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 40449106096     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Differentiated thyroid carcinoma: treatment and follow-up. Guidelines SIE-AIMN-AIFM; 2004.
2. Pace L, Klain M, Albanese C, Salvatore B, Storto G, Soricelli A et al. Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment. Eur J Nucl Med Mol maging 2006;33:179-83.
3. Filesi M, Signore A, Ventroni G, Melacrinis FF, Ronga G. Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases. J Nucl Med 1998;39: 1542-6 '
4. Stokkel MPM, Duchateau CSJ, Dragoiescu C. The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. Q J Nucl Med Mol Imaging 2006;50:78-87.
5. Bomanji JB, Costa DC, Ell PJ. Clinical role of posiron emission tomography in oncology. Lancet Oncol 2001;2:157-64.
6. Schoder H, Yeung HWD. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med 2004;34:180-97.
7. Feine U. Fluor 18-deoxyglucose positron emission tomograph in differentiated thyroid cancer. Eur J Endocrinol 1998; 138:4927
8. Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Diedein M et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547-52.
9. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G et al. Prognostic value of 18-F-fluorodeoxyglucose positron emission tomograhy scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000;85:1107-13.
10. Alnafisi NS, Driedger AA, Coates G, Moote DJ, Raphael SJ. FDG PET of recurrent or metastatic I-negative papillary thyroid carcinoma Nucl Med 2000;41:1010-5.
11. Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006;47:616-24.
12. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-ray. J Nucl Med 1988;29:1790-4.
13. Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131-I whole body scan: comparison of patients treated with high 131-I activities versus untreated patients. J Clin Endocrinol Metab 2001;86:4092-7.
14. Lind P. I-131 whole body scintigraphy in thyroid cancer patients. Q J Nucl Med 1999;43:188-94.
15. Lind P. Should high hTg levels in the absence of iodine uptake be treated? Eur J Nucl Med 2003;30:157-60.
16. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986;63:960-7.
17. Nemec J, Rohling S, Zamrazil V, Pohunkova D. Comparison of the distribution of diagnostic and thyroablative 1-131 in the evaluation of differentiated thyroid cancer. J Nucl Med 1979;20:92-7.
18. Pacini F, Lari R, Mazzeo S, Grasso L, Taddei D, Pinchera A. Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol 1985;23:405-11.
19. Sherman SI, Tielens ET, Sostre S, Wharam MD Jr, Ladenson PW. Clinical utility of post treatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994;78:629-34.
20. Reynolds JC. Percent 131-I uptake and post-therapy 131-I scans: their role in the management of thyroid cancer. Thyroid 1997;7:281-4.
21. Venkataraman GM, Yatin M, Ain KB. Cloning of the human sodium-iodine symporter promoter and characterization in a different human thyroid cell line. Thyroid 1998;8:63-9.
22. +/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 1999;84:3228-34.
23. Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P et al. Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab 1998;83:2493-6.
24. 131I scanning results after therapy. J Nucl Med 2001;42:1464-9.
25. Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131 -iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468-72.
26. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997;24:1342-8.
27. 131I whole-body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999;84:2291-302.
28. Lind P, Kohlfurst S. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin Nucl Med 2006;36:194-205.
29. 131I scan. J Nucl Med 2001;42:71-6.
30. 18F]fluoro-D-glucose-positron emission tomography/ computer tomography diagnosis of patients with recurrent papillary thyroid cancer. Mol Imaging Biol 2006;8:309-14.
31. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW et al. Real time prognosis for metastatic thyroid carcinoma based on FDG-PET scanning. J Clin Endocrinol Metab 2006;91:498-505.
32. Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004;89:91-5.
33. Moog F, Linke R, Manthey N, Tiling R, Knesewitsch P, Tatsch K et al. Influence of thyroid-stimulating hormone levels on uptake of fdg in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 2000;41:1989-95.
34. 18F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2002; 29:641-7.
35. 18F] fluorodeoxyglucose in human thyroid cells in vitro. Eur J Nucl Med Mol Imaging 2004; 31:507-12.
36. 131I-Iodide. J Nucl Med 2006;47:1382-8.
37. Sisson JC, Ackermann RJ, Meyer MA. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 1993;77:1090-4.
38. Lietzenmayer R, Muller-Berg M, Thelen MH, Dohmen BM, Muller-Schauenburg W, Bares R. Follow-up after radioiodine treatment of differentiated thyroid cancer. Nuklearmedizin 1998;37:A23.
39. Schonberger J, Ruschoff J, Grimm D, Marienhagen J, Rummele P, Meyringer R et al. Glucose transporter 1 gene expression is related to thyroid neoplasm with an unforable prognosis: an immuno-histochemical study. Thyroid 2002;12:747-54.
40. Nahas Z, Goldenberg D, Fakhry C, Ewertz M, Zeiger M, Ladenson PW et al. The role of positron emission tomograph/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 2005;115:237-43.
41. 131I. Nuklearmedizin 1995;34:127-34.
42. 131I whole-body scan. J Nucl Med 1999;40:986-92.